Novel antibody-independent receptor-binding SPR-based assay for rapid measurement of influenza vaccine potency
Identifieur interne : 001055 ( Main/Exploration ); précédent : 001054; suivant : 001056Novel antibody-independent receptor-binding SPR-based assay for rapid measurement of influenza vaccine potency
Auteurs : Surender Khurana [États-Unis] ; Lisa R. King [États-Unis] ; Jody Manischewitz [États-Unis] ; Elizabeth M. Coyle [États-Unis] ; Hana Golding [États-Unis]Source :
- Vaccine [ 0264-410X ] ; 2014.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Vaccin.
English descriptors
- KwdEn :
Abstract
A WHO workshop organized following the 2009 H1N1 pandemic recommended development of alternative influenza vaccine potency assays as high priority that could expedite the release of vaccine lots in the face of future influenza pandemics. We have developed an antibody independent, simple, high throughput receptor-binding SPR-based potency assay, which does not require any reference antisera and could be used for rapid HA quantitation and vaccine release in pandemic scenarios. The assay utilizes synthetic glycans with sialic acid (SA) of either α-2,6 or α-2,3 linkage to galactose. Only functionally active forms of HA (trimers and oligomers) recognize the SA-glycans and are quantified in this receptor-binding SPR assay. The SA-glycan SPR assay demonstrated broad dynamic range for quantitation of HA content in influenza vaccines from different manufacturers for both seasonal (A/H1N1, A/H3N2, B lineages) and pandemic influenza (A/H5N1, A/H7N9) strains with high reproducibility and low variability across multiple assays. In addition, the SA-glycan SPR assay is indicative of active HA stability, and can accurately quantify HA content in alum and oil-in-water adjuvanted influenza vaccines. Importantly, there was a good agreement between HA content determined by the SPR-based potency assay and the traditional SRID assay.
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000119
- to stream PascalFrancis, to step Curation: 001D00
- to stream PascalFrancis, to step Checkpoint: 000063
- to stream Main, to step Merge: 001064
- to stream Main, to step Curation: 001055
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Novel antibody-independent receptor-binding SPR-based assay for rapid measurement of influenza vaccine potency</title><author><name sortKey="Khurana, Surender" sort="Khurana, Surender" uniqKey="Khurana S" first="Surender" last="Khurana">Surender Khurana</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration</s1><s2>Bethesda, MD 20892</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="King, Lisa R" sort="King, Lisa R" uniqKey="King L" first="Lisa R." last="King">Lisa R. King</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration</s1><s2>Bethesda, MD 20892</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Manischewitz, Jody" sort="Manischewitz, Jody" uniqKey="Manischewitz J" first="Jody" last="Manischewitz">Jody Manischewitz</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration</s1><s2>Bethesda, MD 20892</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Coyle, Elizabeth M" sort="Coyle, Elizabeth M" uniqKey="Coyle E" first="Elizabeth M." last="Coyle">Elizabeth M. Coyle</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration</s1><s2>Bethesda, MD 20892</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Golding, Hana" sort="Golding, Hana" uniqKey="Golding H" first="Hana" last="Golding">Hana Golding</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration</s1><s2>Bethesda, MD 20892</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">14-0110710</idno><date when="2014">2014</date><idno type="stanalyst">PASCAL 14-0110710 INIST</idno><idno type="RBID">Pascal:14-0110710</idno><idno type="wicri:Area/PascalFrancis/Corpus">000119</idno><idno type="wicri:Area/PascalFrancis/Curation">001D00</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000063</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000063</idno><idno type="wicri:doubleKey">0264-410X:2014:Khurana S:novel:antibody:independent</idno><idno type="wicri:Area/Main/Merge">001064</idno><idno type="wicri:Area/Main/Curation">001055</idno><idno type="wicri:Area/Main/Exploration">001055</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Novel antibody-independent receptor-binding SPR-based assay for rapid measurement of influenza vaccine potency</title><author><name sortKey="Khurana, Surender" sort="Khurana, Surender" uniqKey="Khurana S" first="Surender" last="Khurana">Surender Khurana</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration</s1><s2>Bethesda, MD 20892</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="King, Lisa R" sort="King, Lisa R" uniqKey="King L" first="Lisa R." last="King">Lisa R. King</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration</s1><s2>Bethesda, MD 20892</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Manischewitz, Jody" sort="Manischewitz, Jody" uniqKey="Manischewitz J" first="Jody" last="Manischewitz">Jody Manischewitz</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration</s1><s2>Bethesda, MD 20892</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Coyle, Elizabeth M" sort="Coyle, Elizabeth M" uniqKey="Coyle E" first="Elizabeth M." last="Coyle">Elizabeth M. Coyle</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration</s1><s2>Bethesda, MD 20892</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Golding, Hana" sort="Golding, Hana" uniqKey="Golding H" first="Hana" last="Golding">Hana Golding</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration</s1><s2>Bethesda, MD 20892</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author></analytic><series><title level="j" type="main">Vaccine</title><title level="j" type="abbreviated">Vaccine</title><idno type="ISSN">0264-410X</idno><imprint><date when="2014">2014</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Vaccine</title><title level="j" type="abbreviated">Vaccine</title><idno type="ISSN">0264-410X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibody</term><term>Hemagglutinin</term><term>Influenza</term><term>Vaccine</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Anticorps</term><term>Vaccin</term><term>Hémagglutinine</term><term>Grippe</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Vaccin</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A WHO workshop organized following the 2009 H1N1 pandemic recommended development of alternative influenza vaccine potency assays as high priority that could expedite the release of vaccine lots in the face of future influenza pandemics. We have developed an antibody independent, simple, high throughput receptor-binding SPR-based potency assay, which does not require any reference antisera and could be used for rapid HA quantitation and vaccine release in pandemic scenarios. The assay utilizes synthetic glycans with sialic acid (SA) of either α-2,6 or α-2,3 linkage to galactose. Only functionally active forms of HA (trimers and oligomers) recognize the SA-glycans and are quantified in this receptor-binding SPR assay. The SA-glycan SPR assay demonstrated broad dynamic range for quantitation of HA content in influenza vaccines from different manufacturers for both seasonal (A/H1N1, A/H3N2, B lineages) and pandemic influenza (A/H5N1, A/H7N9) strains with high reproducibility and low variability across multiple assays. In addition, the SA-glycan SPR assay is indicative of active HA stability, and can accurately quantify HA content in alum and oil-in-water adjuvanted influenza vaccines. Importantly, there was a good agreement between HA content determined by the SPR-based potency assay and the traditional SRID assay.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Maryland</li></region></list><tree><country name="États-Unis"><region name="Maryland"><name sortKey="Khurana, Surender" sort="Khurana, Surender" uniqKey="Khurana S" first="Surender" last="Khurana">Surender Khurana</name></region><name sortKey="Coyle, Elizabeth M" sort="Coyle, Elizabeth M" uniqKey="Coyle E" first="Elizabeth M." last="Coyle">Elizabeth M. Coyle</name><name sortKey="Golding, Hana" sort="Golding, Hana" uniqKey="Golding H" first="Hana" last="Golding">Hana Golding</name><name sortKey="King, Lisa R" sort="King, Lisa R" uniqKey="King L" first="Lisa R." last="King">Lisa R. King</name><name sortKey="Manischewitz, Jody" sort="Manischewitz, Jody" uniqKey="Manischewitz J" first="Jody" last="Manischewitz">Jody Manischewitz</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001055 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001055 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:14-0110710
|texte= Novel antibody-independent receptor-binding SPR-based assay for rapid measurement of influenza vaccine potency
}}
| This area was generated with Dilib version V0.6.34. |  |